Strategies for active TNF-α vaccination in rheumatoid arthritis treatment

Vaccine. 2013 Aug 28;31(38):4063-8. doi: 10.1016/j.vaccine.2013.06.101. Epub 2013 Jul 8.

Abstract

Local overexpression of tumor necrosis factors alpha (TNF-α) is critically involved in the inflammatory response and tissue destruction of rheumatoid arthritis (RA). Currently, the blockade of TNF-α by passive immunotherapy is indeed efficacious in the treatment of RA, but it still present some disadvantages. Induction of high level of anti-TNF-α neutralizing autoantibodies by TNF-α autovaccine has been developed to avoid these shortcomings. This review is to briefly introduce several vaccination approaches that have been used to induce a B cell response, including coupled TNF-α (entire/peptide) with a carrier protein, modified TNF-α with foreign Th cell epitopes, and engineered DNA vaccine. These methods showed remarkable therapeutic efficiency in experimental animals which indicated that active TNF-α immunization would be a promising and cost-effective new treatment option for RA.

Keywords: Active vaccination; Rheumatoid arthritis; TNF-α.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Arthritis, Rheumatoid / immunology*
  • Arthritis, Rheumatoid / therapy*
  • Autoantibodies / immunology
  • Epitopes
  • Hemocyanins / immunology
  • Humans
  • Tumor Necrosis Factor-alpha / immunology*
  • Tumor Necrosis Factor-alpha / metabolism
  • Vaccination / methods*
  • Vaccines, DNA / pharmacology

Substances

  • Autoantibodies
  • Epitopes
  • Tumor Necrosis Factor-alpha
  • Vaccines, DNA
  • Hemocyanins
  • keyhole-limpet hemocyanin